SCHEMBL3607859

SCHEMBL3607859

CC(C)(C)[Si](C)(C)OCc1cccc(OC[C@H]2CCCN2C(=O)O)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.38
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
SPHK2 Q9NRA0 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
GRM5 P41594 1/20 0.36
GRM1 Q13255 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CNR2 P34972 2/20 0.35
ABHD6 Q9BV23 1/20 0.35
DAGLA Q9Y4D2 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605764 0.97 RAB9A (0.39) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL3606003 0.83 CNR2 (0.40) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL3602873 0.83 DAGLB (0.40) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL3608576 0.80 DAGLB (0.43) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL3615900 0.80 CNR2 (0.42) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL3602535 0.75 HRH3 (0.37) KMT2A
SCHEMBL4566643 0.74 KCNH2 (0.33) POLBRIPK1
SCHEMBL5342375 0.72 ALOX5AP (0.54) LMNAPOLBF2RL3
SCHEMBL6475389 0.71 PREP (0.49) LMNA
SCHEMBL6475398 0.71 PREP (0.49) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723331-B2 Thienopyrimidine compounds and uses thereof ASTRAZENECA AB (SE) 2010-05-25 US disclosed
US-20080051405-A1 Therapeutic Agents ASTRAZENECA AB (SE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051405-A1 Therapeutic Agents GPR119, HTT, IAPP CYP2D6 2258/4885DPP4 593/4885DPP8 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.